Skip to Content
7

McKesson

Courtesy of Michael Prince/McKesson
  • Previous Rank6
  • Revenues ($M)$208,357.0
  • Revenue Percent Change4.9%
  • Profits ($M)$67.0
  • Profits Percent Change-98.7%
  • Assets ($M)$60,381.0
  • Employees68,000

America’s largest drug distributor is under new leadership after its long-serving CEO—and consistently one of the country’s highest paid—John Hammergren retired in April. He left the wholesaler much expanded from when he began his run at the company 17 years ago. That trend continued in 2018: Revenue grew 4.9% due to rising drug prices, increased sales to existing customers, and through acquisitions. Profits took a hit partly because of one-time charges involving its European business and Rexall, a Canadian drug store chain McKesson acquired in 2016. Like its two major competitors, McKesson is facing a growing number of lawsuits for its alleged role in the nation’s opioid epidemic; it has denied any wrongdoing.

Subscribe to Fortune’s CEO Daily newsletter for must-read business news and analysis.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Brian S. Tyler
CEO Title
President, Chief Executive Officer & Director
Sector
Health Care
Industry
Wholesalers: Health Care
HQ Location
Irving, Texas
Websitehttp://www.mckesson.com
Years on Fortune 500 List25
Employees68,000
Figures are for fiscal year ended March 31, 2018.

McKesson Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$208,357.04.9%
Profits ($M)$67.0-98.7%
Assets ($M)$60,381.0-
Total Stockholder Equity ($M)$9,804.0-

Profit Ratios

Profit as % of Revenues0.0%
Profits as % of Assets0.1%
Profits as % of Stockholder Equity0.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)0.32
EPS % Change (from 2017)-98.6%
EPS % Change (5 year annual rate)-43.6%
EPS % Change (10 year annual rate)-20.9%

Total Return

Total Return to Investors (2018)-28.4%
Total Return to Investors (5 year, annualized)-6.7%
Total Return to Investors (10 year, annualized)12.0%